Clinical experience with pegaptanib sodium
Chiara Rosina, Ferdinando Bottoni, Giovanni StaurenghiLuigi Sacco Hospital, University of Milano, ItalyAbstract: Pegaptanib sodium (Macugen®) blocks the extracellular vascular endothelial growth factor (VEGF) isoform VEGF165, whose elevated levels are associated with the development of c...
Guardado en:
Autores principales: | Chiara Rosina, Ferdinando Bottoni, Giovanni Staurenghi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a2fea8920124e42b8807847999e82d5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pegaptanib sodium for neovascular age-related macular degeneration: clinical experience in the UK
por: Sobha Sivaprasad, et al.
Publicado: (2008) -
Pegaptanib sodium treatment in neovascular age-related macular degeneration: clinical experience in Germany
por: Nikolaus Feucht, et al.
Publicado: (2008) -
Role of pegaptanib sodium in the treatment of neovascular age-related macular degeneration
por: Sobha Sivaprasad
Publicado: (2008) -
Population pharmacokinetics of pegaptanib sodium (Macugen®) in patients with diabetic macular edema
por: Basile AS, et al.
Publicado: (2015) -
An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edema
por: Sivaprasad S, et al.
Publicado: (2014)